← All Spruce Biosciences, INC filings

Spruce Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SPRB
Spruce Biosciences, INC
10-K: Spruce Biosciences Faces Going Concern Doubts Despite Pipeline Progress
Spruce Biosciences reports significant net losses and raises substantial doubt about its ability to continue as a going concern despite advancements in its clinical development programs.
NASDAQ
SPRB
Spruce Biosciences, INC
10-K: Spruce Biosciences Reports Mixed Results in CAH Trials, Shifts Focus to Pediatric and Glucocorticoid-Sparing Therapies
Spruce Biosciences terminates one Phase 2b trial for classic CAH after failing to meet primary endpoints, while another trial and a pediatric study show promise, leading to a strategic shift in focus.